Point-of-Care Infectious Disease Diagnostics & Testing Market Size, Share & Trends Analysis Report By Product (HIV POC, Clostridium difficile POC, HBV POC, Pneumonia or Streptococcus associated infections, Respiratory syncytial virus (RSV) POC, HPV POC, Influenza/Flu POC, Other Infectious Disease POC), By Applications (Hospitals, Clinics, Home, Assisted Living Healthcare Facilities, Laboratories, Others), By End Use, By Region, and Segment Forecasts - 2035

Opportunity

""Multiplex and home testing are opening new decentralized diagnostic opportunities.""

Multi-pathogen respiratory testing provides one of the strongest growth opportunities because it allows healthcare providers to obtain clinically actionable answers without performing several individual assays. New CLIA-waived molecular systems can process between 5 and 15 respiratory and sore-throat targets in approximately 15 minutes, while configurable instruments can operate as many as 4 tests simultaneously. This approach is attractive to urgent-care centers, Clinics, Hospitals, and Assisted Living Healthcare Facilities because patient symptoms often do not identify the responsible pathogen. Wider adoption could also improve antimicrobial stewardship by helping clinicians distinguish bacterial and viral disease during the first appointment. The opportunity extends beyond respiratory disease because manufacturers are developing point-of-care platforms for sexually transmitted infections and other syndromic categories using the same compact instruments.

Home testing represents another major opportunity as regulatory pathways expand beyond single-analyte COVID-19 products. By December 2025, U.S. regulators had cleared a rapid test capable of detecting influenza A, influenza B, COVID-19, and RSV in one product, demonstrating how consumer testing is moving toward multi-analyte respiratory diagnosis. Home applications currently represent an estimated 10% of the supplied application structure but are positioned to grow faster than traditional laboratory settings as consumers become more familiar with self-testing. HIV self-testing provides another opportunity, and WHO prequalification pathways specifically include rapid HIV diagnostics intended for self-testing. Future home products can combine smartphone interpretation, automatic result capture, telehealth linkage, and digital instructions, helping convert point-of-care diagnostics from isolated physical tests into connected care services.

Challenge

""Maintaining accuracy across multiple pathogens and changing variants remains technically demanding.""

Multiplex point-of-care testing creates substantial analytical complexity because manufacturers must maintain high sensitivity and specificity across multiple pathogens within one cartridge or strip. A 15-target respiratory assay must correctly differentiate viruses and bacteria that may coexist in the same specimen while avoiding cross-reactivity. Molecular platforms also need primers and probes that remain effective as viral genomes change over time. Influenza demonstrates this challenge because circulating strains continuously evolve, while emerging influenza subtypes may not be differentiated by standard assays. Current U.S. influenza diagnostic listings include approximately 72 test entries across different technologies, illustrating both extensive competition and the need for continuing regulatory oversight. Manufacturers must therefore perform ongoing surveillance and periodically update assay designs when pathogen evolution threatens performance. 

Interpretation creates another challenge when point-of-care systems detect multiple organisms. A positive molecular result may identify pathogen nucleic acid without automatically determining disease severity, infectiousness, or whether another condition is responsible for symptoms. Pneumonia panels can detect more than 30 targets, and broad syndromic systems must be integrated with clinical assessment rather than used as independent diagnostic decision makers. High-complexity panels can also detect organisms that are colonizing rather than causing active disease. Training therefore remains important even when sample preparation is reduced to approximately 2 minutes. Data-management systems are increasingly used to track pathogen trends, utilization, stock levels, and testing patterns, helping clinicians and laboratories interpret high-volume point-of-care results in a wider epidemiological context.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The Point-of-Care Infectious Disease Diagnostics & Testing Market is segmented by product type into HIV POC, Clostridium difficile POC, HBV POC, Pneumonia or Streptococcus associated infections, Respiratory syncytial virus (RSV) POC, HPV POC, Influenza/Flu POC, and Other Infectious Disease POC. Influenza/Flu POC is estimated to account for approximately 22% market share, followed by Other Infectious Disease POC at 20%, HIV POC at 15%, Pneumonia or Streptococcus associated infections at 13%, RSV POC at 10%, HBV POC at 8%, HPV POC at 7%, and Clostridium difficile POC at approximately 5%. Applications are led by Hospitals at approximately 34%, Clinics at 26%, Laboratories at 15%, Home at 10%, Assisted Living Healthcare Facilities at 8%, and Others at approximately 7%.

By Types

HIV POC: HIV POC accounts for approximately 15% market share and remains a strategically important diagnostic category because approximately 40.9 million people were living with HIV worldwide in 2025. About 1.2 million people newly acquired HIV during the year, sustaining requirements for screening, confirmatory pathways, antenatal testing, community testing, and self-testing. Point-of-care HIV products can generate results within approximately 20 minutes without complex instrumentation, making them suitable for decentralized settings. WHO continues to encourage lower-cost quality-assured rapid HIV diagnostics as the first assay in national testing algorithms where appropriate. Integration is also increasing, with a 2025 prequalified bundled testing approach simultaneously addressing HIV, hepatitis B, and syphilis in antenatal care.

Clostridium difficile POC: Clostridium difficile POC represents approximately 5% market share and supports rapid identification of a clinically important healthcare-associated gastrointestinal infection. Testing demand is concentrated in Hospitals, long-term care, and Laboratories because infection frequently occurs following antibiotic exposure or healthcare contact. Point-of-care molecular technologies can reduce time between specimen collection and isolation decisions compared with batch testing. The segment remains smaller than respiratory diagnostics because testing is driven primarily by symptomatic patients rather than population-wide seasonal screening. Demand nevertheless remains clinically important because rapid identification can support infection control and help differentiate C. difficile from other causes of diarrhea.

HBV POC: HBV POC accounts for approximately 8% market share and is supported by the large global chronic hepatitis B population. Approximately 240 million people were living with chronic HBV infection in 2024, yet fewer than 5% were receiving treatment, illustrating major diagnosis and care gaps. Point-of-care HBV testing is especially important in maternal health, community screening, blood safety, and low-resource settings where centralized laboratory access is limited. The first WHO-prequalified bundled HIV, HBV, and syphilis rapid testing panel was introduced in 2025, strengthening the role of integrated antenatal diagnostics. Africa remains particularly important because it accounted for approximately 68% of new hepatitis B infections in 2024. 

Pneumonia or Streptococcus associated infections: Pneumonia or Streptococcus associated infections account for approximately 13% market share and are increasingly addressed using molecular syndromic testing. Compact point-of-care systems can identify group A Streptococcus alongside common respiratory viruses in approximately 15 minutes, while broader laboratory pneumonia panels identify up to 34 targets and 7 genetic antimicrobial-resistance markers. Rapid streptococcal diagnosis is particularly valuable because molecular platforms can reduce false-negative results compared with conventional antigen testing and may avoid additional culture confirmation. As antimicrobial stewardship becomes more important, rapid differentiation between bacterial and viral respiratory disease is expected to support segment expansion.

Respiratory syncytial virus (RSV) POC: Respiratory syncytial virus (RSV) POC represents approximately 10% market share and is supported by significant pediatric and older-adult disease burden. RSV causes more than 3.6 million hospitalizations and approximately 100,000 deaths each year among children younger than 5 years. Point-of-care molecular assays can provide RSV results in 13 to 20 minutes and can combine RSV with influenza A/B and COVID-19 testing. Demand is increasing as preventive vaccines and monoclonal antibodies create greater clinical interest in identifying respiratory pathogens accurately. Pediatric Hospitals, Clinics, urgent care, and Assisted Living Healthcare Facilities are important testing environments because infants and older adults experience disproportionately severe disease.

HPV POC: HPV POC accounts for approximately 7% market share and provides an emerging opportunity as cervical cancer prevention strategies increasingly combine vaccination and screening. HPV testing has historically been concentrated in central Laboratories, but decentralized molecular technology can increase access in lower-resource environments. The segment is particularly relevant where women face long travel distances or may not return for laboratory results. A same-visit diagnostic pathway can potentially reduce loss to follow-up by allowing screening and care decisions to occur during 1 encounter. Future growth will depend on simplified sample collection, self-sampling, compact molecular systems, and integration with national cervical cancer screening programs.

Influenza/Flu POC: Influenza/Flu POC leads with approximately 22% market share because influenza produces recurring seasonal testing demand and symptoms overlap with RSV, COVID-19, and other respiratory infections. Current rapid molecular influenza assays provide results in approximately 15 to 30 minutes with sensitivity around 90% to 95%, while selected platforms provide early positive results in approximately 5 minutes. Influenza point-of-care testing is extensively used in urgent-care centers, Hospitals, Clinics, pharmacies, and other near-patient settings. Multi-analyte respiratory testing is strengthening the segment because clinicians increasingly test influenza A/B alongside RSV and other pathogens from one swab.

Other Infectious Disease POC: Other Infectious Disease POC accounts for approximately 20% market share and captures rapid testing outside the 7 specified disease categories. This broad segment includes additional respiratory, sexually transmitted, tropical, and emerging infectious disease applications. New point-of-care platforms increasingly use modular molecular architectures so a single instrument can support multiple future assay menus. Multiplex technology demonstrates the expansion potential, with existing systems capable of running as many as 4 cartridges simultaneously and returning results during a typical outpatient visit. The segment is expected to benefit from faster assay development when emerging pathogens create new public-health requirements.

By Applications

Hospitals: Hospitals dominate with approximately 34% market share because rapid testing supports emergency medicine, inpatient infection control, pediatrics, intensive care, labor and delivery, and antimicrobial stewardship. Hospital point-of-care platforms can reduce diagnostic delays from several hours to approximately 15 to 20 minutes for selected respiratory infections. The ability to distinguish influenza, RSV, COVID-19, and bacterial sore-throat infections during the initial clinical encounter can influence patient placement and treatment. Hospitals also retain central Laboratories, meaning point-of-care testing is generally deployed alongside rather than instead of high-throughput laboratory diagnostics.

Clinics: Clinics represent approximately 26% market share and are one of the strongest environments for compact molecular systems because many patients are treated during one short visit. A point-of-care platform returning results in approximately 13 to 20 minutes can allow the clinician to diagnose, counsel, prescribe, and discharge the patient before they leave. Urgent-care centers and physician offices frequently lack large central laboratories, making CLIA-waived systems particularly valuable. Scalable molecular platforms capable of running 1 to 4 modules allow Clinics to match throughput to patient volume without installing full laboratory automation.

Home: Home applications account for approximately 10% market share and are expanding from COVID-19 toward influenza and multi-pathogen respiratory diagnostics. U.S. regulatory clearances during 2025 included over-the-counter tests combining RSV, influenza A/B, and COVID-19, demonstrating the move toward broader self-testing. Home diagnostics reduce travel and can provide information before patients enter crowded healthcare environments. Challenges include specimen collection and interpretation, but smartphone guidance and telehealth integration can improve usability. Continued regulatory acceptance could make Home one of the fastest-growing supplied application segments through 2035.

Assisted Living Healthcare Facilities: Assisted Living Healthcare Facilities represent approximately 8% market share and benefit from rapid infectious disease testing because residents are often older and vulnerable to respiratory outbreaks. RSV, influenza, and other respiratory pathogens can spread quickly in congregate settings housing dozens or hundreds of residents. Near-patient diagnostics can identify infections during the first clinical assessment and support isolation decisions. The segment is becoming more important as RSV is increasingly recognized as a significant cause of severe disease among older adults in addition to children.

Laboratories: Laboratories account for approximately 15% market share and remain important for validation, confirmatory testing, quality oversight, and lower-throughput satellite locations. Although point-of-care testing shifts diagnostics closer to patients, Laboratories often manage instrument connectivity, reagent quality, proficiency programs, and result integration. Compact molecular systems are increasingly placed within laboratory networks because tests can return results in approximately 15 minutes while requiring minimal hands-on time. Laboratory professionals also provide governance to ensure decentralized testing remains consistent across dozens of hospital departments or outpatient sites.

Others: Others represent approximately 7% market share and include community testing programs, pharmacies, mobile health services, workplaces, public-health programs, and other decentralized environments. Rapid diagnostics requiring no additional equipment can be particularly valuable in temporary testing sites and low-resource communities. Technology-transfer initiatives announced in 2025 demonstrate how rapid tests with results available within approximately 20 minutes can be locally manufactured and deployed across public-health networks. These applications expand the market beyond conventional healthcare institutions.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to account for approximately 39% of the Point-of-Care Infectious Disease Diagnostics & Testing Market and remains the leading region because of extensive urgent-care networks, advanced molecular diagnostics, strong insurance coverage, home-testing acceptance, and an established regulatory pathway for CLIA-waived assays. The United States supports a broad installed base of compact infectious disease instruments in physician offices, Hospitals, Clinics, and emergency departments. Influenza testing is particularly developed, with approximately 72 diagnostic products included in the current U.S. influenza testing framework across antigen and molecular technologies. Regulatory activity during 2025 continued expanding the number of multi-analyte respiratory options available for decentralized use.

The region is also at the forefront of molecular POC adoption. In April 2025, a 4-target molecular respiratory assay for SARS-CoV-2, influenza A/B, and RSV received 510(k) clearance and CLIA waiver, providing results in approximately 20 minutes. Additional home respiratory products received clearances during the final months of 2025, broadening decentralized diagnosis. The combination of professional point-of-care molecular systems and consumer self-tests creates a layered market in which patients can be tested at home, in pharmacies, physician offices, urgent care, emergency departments, or central Laboratories according to clinical need.

Europe

Europe represents approximately 26% market share and maintains strong adoption of respiratory molecular testing, HIV diagnostics, sexually transmitted infection testing, and community screening. European healthcare systems are increasingly interested in rapid diagnostics that reduce unnecessary antibiotic prescribing and improve same-visit treatment decisions. Compact molecular platforms capable of returning respiratory results within approximately 15 to 20 minutes are particularly relevant to primary-care and emergency settings. Europe also has extensive public-health screening systems that support HIV POC and HBV POC adoption, particularly for high-risk populations and antenatal care.

Antimicrobial stewardship is an important regional growth factor. Rapid differentiation between viral and bacterial respiratory disease can reduce empirical antibiotic use, while multiplex diagnostics allow clinicians to test several likely causes rather than ordering sequential assays. European systems are also increasingly connecting decentralized instruments to laboratory information networks so point-of-care results remain visible in centralized patient records. Modular systems capable of operating as many as 4 simultaneous tests provide scalable throughput for smaller facilities. The region is expected to maintain a significant share through 2035 as aging populations increase influenza and RSV testing requirements.

Asia-Pacific

Asia-Pacific accounts for approximately 23% market share and is projected to record the fastest growth at around 6.1% annually. China, India, Japan, South Korea, Southeast Asia, and Australia combine large populations with increasing diagnostic access. The region contains more than 4 billion people, creating enormous potential for affordable point-of-care infectious disease testing. Respiratory diagnostics are gaining importance as Clinics and Hospitals expand molecular capability, while HIV POC and HBV POC remain critical in countries with substantial infectious disease burdens. Local diagnostic manufacturing is also increasing, supporting lower costs and broader distribution.

HBV testing provides a particularly important opportunity because chronic hepatitis B affects approximately 240 million people globally, with substantial disease burden across Asia. Expanding maternal screening and treatment linkage can increase HBV POC utilization. Home testing is also likely to grow as smartphone use and e-commerce distribution broaden access to consumer diagnostics. Japan and South Korea have advanced healthcare systems capable of adopting higher-cost molecular products, while India and Southeast Asia create opportunities for lower-cost rapid formats. The resulting diversity supports both instrument-based and visually interpreted POC technologies.

Middle East & Africa

Middle East & Africa represents approximately 8% market share but has some of the strongest unmet testing requirements. The African region carries the largest global HIV burden, with approximately two-thirds of people living with HIV concentrated in the region during 2024. HIV POC therefore remains a foundational testing technology because rapid diagnostics can operate in health facilities without conventional laboratory infrastructure. HBV is also significant, with Africa accounting for approximately 68% of new hepatitis B infections recorded in 2024. These disease burdens make affordable rapid testing strategically important for maternal health, community screening, and linkage to treatment. 

Local manufacturing is becoming increasingly important to regional market development. A 2025 international sublicensing agreement enabled a Nigerian health technology company to begin development and manufacturing of rapid diagnostic tests using transferred technology. Initial production is focused on HIV, with the platform capable of producing results within approximately 20 minutes and supporting future applications such as malaria and syphilis. Local manufacturing can shorten supply chains and reduce dependence on imported diagnostics. Gulf countries provide a different opportunity through advanced Hospitals and higher adoption of molecular respiratory systems, creating a dual market spanning low-cost rapid tests and premium multiplex platforms.

List of Top Point-of-Care Infectious Disease Diagnostics & Testing Companies

• Abbott
• Thermo Fisher Scientific Inc
• Roche
• Siemens Healthineers
• BD & Company
• Chembio Diagnostics Inc.
• Trinity Biotech
• Cardinal Health
• Quest Diagnostics Inc.
• Bio-Rad Labs Inc.
• bioMérieux SA
• Sight Diagnostics Ltd.
• Gene POC
• Trivitron Healthcare
• OJ-Bio Ltd.
• Ortho-Clinical Diagnostics

Top 2 Companies Market Share

Abbott: Abbott is estimated to hold approximately 18% share within the supplied competitive framework, supported by extensive rapid diagnostics, molecular point-of-care testing, HIV testing, and respiratory products. Its ID NOW system provides molecular influenza A/B results in 13 minutes or less and can produce early positive influenza results in approximately 5 minutes. The platform also supports RSV and Strep A testing, providing a broader menu through one compact instrument. Abbott's strength in both instrument-based molecular testing and rapid lateral-flow diagnostics enables the company to address multiple application environments from physician offices to community testing.

Roche: Roche is estimated to hold approximately 15% share within the supplied competitive framework, giving the top 2 companies a combined estimated share of approximately 33%. Its cobas liat platform supports automated real-time PCR at the point of care, including a 4-target assay for SARS-CoV-2, influenza A, influenza B, and RSV. The test received U.S. clearance in April 2025, provides results in approximately 20 minutes, requires less than 1 minute of hands-on time, and is authorized for CLIA-waived settings. Roche also expanded the platform with sexually transmitted infection testing, strengthening menu diversification beyond respiratory disease. 

Investment Analysis

Investment in the Point-of-Care Infectious Disease Diagnostics & Testing Market is increasingly concentrated on multiplex molecular platforms, cartridge manufacturing, decentralized connectivity, and home diagnostics. Molecular systems are attractive because one small instrument can support several infectious disease assays while delivering results in approximately 15 to 20 minutes. Modular architectures improve capital efficiency by allowing customers to begin with 1 module and expand to as many as 4 when testing volumes increase. Investment also extends into cloud-based data management because decentralized networks may contain hundreds of instruments across Hospitals and Clinics. Connectivity allows laboratories to track utilization, pathogen positivity, inventory, operator performance, and quality control from centralized dashboards.

Local manufacturing represents another investment priority as governments seek more resilient diagnostic supply chains. The 2025 technology-transfer initiative supporting rapid diagnostic production in Nigeria illustrates the opportunity to manufacture tests nearer to high-burden populations. Africa remains particularly attractive for HIV POC and HBV POC because roughly two-thirds of the global HIV population is concentrated in the region and approximately 68% of new HBV infections in 2024 occurred there. Asia-Pacific also offers substantial investment potential because regional growth is estimated near 6.1% annually within the current framework. Companies able to combine low-cost lateral-flow tests with higher-performance molecular platforms can address multiple levels of healthcare infrastructure.

New Product Development

New product development is strongly focused on multiplex respiratory testing. In April 2025, a compact molecular assay received U.S. clearance and CLIA waiver for simultaneous detection of SARS-CoV-2, influenza A, influenza B, and RSV. The system provides results in approximately 20 minutes with less than 1 minute of hands-on time. Another molecular platform offers respiratory and sore-throat panels capable of detecting either 5 or as many as 15 targets in approximately 15 minutes. These products demonstrate how developers are replacing sequential single-pathogen testing with syndromic panels capable of providing a broader diagnostic answer during one patient visit. 

Rapid-test development is also expanding into integrated screening and consumer self-testing. In July 2025, WHO prequalified the first bundled rapid diagnostic set addressing HIV, HBV, and syphilis for antenatal screening. In December 2025, a U.S. rapid respiratory product received clearance for influenza A/B, COVID-19, and RSV detection, illustrating increasing multi-analyte functionality outside instrument-based molecular testing. Future products are expected to combine improved digital readers, smartphone support, simpler sample collection, and connectivity. The most successful technologies will likely provide at least 3 advantages simultaneously: short turnaround time, multiple pathogen detection, and minimal operator complexity. 

Five Recent Developments

• March 2026: Updated U.S. influenza diagnostic guidance highlighted rapid molecular assays with approximately 90% to 95% sensitivity and turnaround times of about 15 to 30 minutes, reinforcing the growing clinical role of CLIA-waived nucleic-acid testing at the point of care. 
• December 2025: A multi-analyte rapid respiratory test received U.S. 510(k) clearance for detection of influenza A, influenza B, COVID-19, and RSV, strengthening the movement toward broader respiratory testing through a single rapid product. 
• August 2025: The BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini received a U.S. CLIA waiver, expanding decentralized multiplex molecular testing with a compact platform that can deliver targeted respiratory and sore-throat results during a typical patient visit.
• July 2025: WHO prequalified the first bundled rapid diagnostic set designed to detect HIV, hepatitis B, and syphilis in antenatal care, creating a 3-infection screening approach intended to expand access and support prevention of mother-to-child transmission.
• June 2024: Roche received U.S. emergency authorization for a 4-in-1 molecular assay capable of detecting SARS-CoV-2, influenza A, influenza B, and RSV from a single respiratory sample in approximately 20 minutes, preceding its 2025 traditional clearance.

Report Coverage

The Point-of-Care Infectious Disease Diagnostics & Testing Market report evaluates industry conditions across the 2026-2035 forecast period using 2025 as the principal baseline. Coverage includes HIV POC, Clostridium difficile POC, HBV POC, Pneumonia or Streptococcus associated infections, Respiratory syncytial virus (RSV) POC, HPV POC, Influenza/Flu POC, and Other Infectious Disease POC. Influenza/Flu POC is estimated to hold approximately 22% market share, Other Infectious Disease POC 20%, HIV POC 15%, Pneumonia or Streptococcus associated infections 13%, RSV POC 10%, HBV POC 8%, HPV POC 7%, and Clostridium difficile POC approximately 5%. Application analysis places Hospitals at 34%, Clinics at 26%, Laboratories at 15%, Home at 10%, Assisted Living Healthcare Facilities at 8%, and Others at approximately 7%.

The competitive assessment covers Abbott, Thermo Fisher Scientific Inc, Roche, Siemens Healthineers, BD & Company, Chembio Diagnostics Inc., Trinity Biotech, Cardinal Health, Quest Diagnostics Inc., Bio-Rad Labs Inc., bioMérieux SA, Sight Diagnostics Ltd., Gene POC, Trivitron Healthcare, OJ-Bio Ltd., and Ortho-Clinical Diagnostics. Current market conditions include molecular respiratory turnaround times approaching 13 to 20 minutes, multiplex systems detecting as many as 15 respiratory and sore-throat targets, approximately 40.9 million people living with HIV in 2025, roughly 240 million people with chronic hepatitis B in 2024, and RSV causing more than 3.6 million annual hospitalizations among children under 5 years. Coverage further evaluates decentralized molecular testing, rapid antigen diagnostics, home testing, multiplex PCR, HIV and HBV screening, respiratory disease, antimicrobial stewardship, regulatory activity, product development, regional adoption, investment, connectivity, and diagnostic manufacturing through 2035.